Racial variation in antidepressant treatment in a Medicaid population

Area of Science:

• Health Services Research
• Medical Sociology
• Psychiatry

Background:

• Racial and socioeconomic disparities in healthcare are well-documented.
• Undertreatment of depression affects all populations but disproportionately impacts minorities and vulnerable groups like Medicaid recipients.
• This study focuses on racial differences in antidepressant use within a Medicaid population.

Purpose of the Study:

• To examine racial disparities in antidepressant prescription patterns among a Medicaid population.
• To assess differences in initial antidepressant receipt and medication class (TCAs vs. SSRIs) based on race.

Main Methods:

• Analysis of a state Medicaid database from 1989-1994.
• Inclusion of 13,065 patients diagnosed with depression (ICD-9-CM criteria).
• Logistic regression used to evaluate treatment differences by race, controlling for covariates.

Main Results:

• African Americans were significantly less likely than whites to receive an antidepressant at diagnosis (27.2% vs. 44.0%, p < .001).
• Among those treated, whites were more likely to receive Selective Serotonin Reuptake Inhibitors (SSRIs) compared to Tricyclic Antidepressants (TCAs) than African Americans.
• These racial differences persisted after adjusting for other patient characteristics.

Conclusions:

• A small fraction of depressed Medicaid patients receive adequate antidepressant treatment.
• Limited access to adequate antidepressant therapy is particularly evident among African Americans within this population.
• Significant racial disparities exist in both the initiation of antidepressant treatment and the choice of medication.